Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 7Hematologic Diseases 7Immunoproliferative Disorders 6Lymphoma, Non-Hodgkin 5Lymphatic Diseases 5Lymphoma 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Vascular Diseases 2Paraproteinemias 2Hemostatic Disorders 2Hemorrhagic Disorders 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 346Cytarabine 282fludarabine phosphate 203Methotrexate 186Filgrastim 159Busulfan 148Etoposide 135Peripheral Blood Stem Cell Transplantation 134fludarabine 128Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 86Mycophenolic Acid 86Whole-Body Irradiation 81Melphalan 79Imatinib Mesylate 69Idarubicin 67Granulocyte Colony-Stimulating Factor 66Mercaptopurine 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × dacetuzumab × Clear all
NCT00283101 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Seagen Inc.

Phase 1/2 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡